Home » Maculopathy, 3,000 intravitreal injections in one year in Aosta – Healthcare

Maculopathy, 3,000 intravitreal injections in one year in Aosta – Healthcare

by admin
Maculopathy, 3,000 intravitreal injections in one year in Aosta – Healthcare

Opened at the beginning of 2023 by the Beauregard ophthalmology complex in Aosta, the clinic for intravitreal injections carried out over 3,000 injections in one year on patients suffering from senile macular degeneration (AMD), “a very widespread chronic pathology, which represents one of main causes of blindness in the population over the age of 55, and it is estimated that in Italy there are approximately 15,000 new cases per year”. This was communicated by the Aosta Valley Local Health Authority.


“This therapy is essential in the wet form of the disease – we read in a note – which affects around 650 patients in Valle d’Aosta. To which must be added another 1,300 affected by the dry form (for which injections cannot yet be prescribed intravitreal, the procedure is awaiting ministerial authorization)”.


For both categories, Optical Coherence Tomography (OCT) is available at the Donnas clinic, an indispensable test in the pre-operative diagnosis and post-operative follow-up of most ocular pathologies requiring surgery. The OCT is connected to a remote reporting service. “Having this service in the area allows us to reach patients in a more widespread way, guaranteeing better access to diagnosis and therefore to treatment. The earlier the diagnosis, the quicker treatment can be resorted to, achieving good results in terms of care and quality of care. life” explains Luca Ventre, director of Ophthalmology.

breaking latest news © Copyright ANSA

See also  PNRR, the President and CEO Vito Cozzoli at "Missione Italia": "We want to strengthen the synergy between Municipalities and Sport and Health"

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy